ADC Structure & Quality Characterization
Antibody-drug conjugates (ADCs) are structurally complex molecules composed of an antibody, linker, and cytotoxic payload, with product quality influenced by conjugation chemistry, drug loading, molecular integrity, and structural heterogeneity. Comprehensive characterization is therefore essential for understanding ADC structure, confirming product identity, and evaluating critical quality attributes throughout development.
Protheragen provides comprehensive ADC structure and quality characterization services using complementary physicochemical, structural, and biochemical analytical approaches. The characterization strategy can be tailored to the ADC format, conjugation chemistry, development stage, and specific quality attributes of interest, supporting process development, formulation development, stability assessment, comparability studies, and CMC development.
Overview of ADC Structure & Quality Characterization
Comprehensive ADC characterization integrates orthogonal analytical techniques to evaluate the molecular structure, purity, heterogeneity, conjugation characteristics, and functional properties of an ADC. Unlike a single analytical test, a multi-attribute characterization strategy provides complementary information and helps establish a more complete understanding of product quality.
Key characterization areas may include molecular identity and mass, primary structure, post-translational modifications (PTMs), higher-order structure, charge heterogeneity, aggregation and fragmentation, drug-to-antibody ratio (DAR), drug distribution, conjugation sites, free payload, and biological activity.
The selection of analytical methods is determined by the specific ADC molecule and its development objectives. Results from complementary characterization studies can be integrated to support product understanding, process optimization, formulation development, stability evaluation, and comparability assessment.
Fig.1 Various characterization tools for antibody-drug conjugates. (Dixit T, et al., 2025)
Our Services
Molecular Identity & Mass Characterization
Molecular identity and molecular mass are evaluated using complementary mass spectrometric and chromatographic approaches. Intact, reduced, or subunit-level analyses can provide information on molecular mass, conjugation-related changes, and product identity.
Primary Structure & Sequence Characterization
Primary structural analysis can assess antibody sequence integrity and identify sequence-related variants or modifications. Peptide mapping and mass spectrometry-based approaches can be applied to confirm sequence coverage and characterize relevant modifications.
Higher-Order Structure Characterization
Higher-order structure analysis evaluates the conformational and structural integrity of the ADC. Depending on the molecule and analytical objective, techniques such as spectroscopic and thermal analysis can be used to investigate secondary and tertiary structural characteristics.
DAR & Drug Distribution Characterization
Drug-to-antibody ratio (DAR) and drug distribution are important attributes of ADCs because conjugation levels can influence potency, pharmacokinetics, stability, and product heterogeneity. Complementary chromatographic and mass spectrometric approaches can be used to determine average DAR and characterize the distribution of drug-loaded species.
Conjugation Site Characterization
Conjugation site analysis provides information on where the linker-payload is attached to the antibody. Mass spectrometry-based approaches can help identify and characterize conjugation sites and evaluate site-specific or heterogeneous conjugation patterns.
Purity & Product-Related Variant Characterization
Characterization of purity and product-related variants may include assessment of aggregates, fragments, charge variants, unconjugated antibody, and other molecular species. Orthogonal analytical methods can provide complementary information for evaluating overall product quality.
PTM & Molecular Modification Characterization
Post-translational modifications and conjugation-related modifications can affect ADC structure and performance. Analytical characterization can investigate relevant modifications such as glycosylation, oxidation, deamidation, glycation, and other molecular changes where applicable.
Biological Activity & Functional Characterization
Where applicable, biological and biochemical assays can be used to evaluate target binding, cellular activity, or other functional characteristics. Functional characterization complements physicochemical analysis to provide a broader assessment of ADC quality.
Major ADC Quality Attributes Characterized
ADC characterization programs can be designed around the critical quality attributes most relevant to the specific molecule.
| Characterization Area |
Representative Attributes |
Typical Analytical Approaches |
| Identity |
Molecular identity, molecular mass |
LC-MS / HRMS, intact mass analysis |
| Primary Structure |
Sequence integrity, peptide-level modifications |
Peptide mapping, LC-MS/MS |
| Higher-Order Structure |
Secondary and tertiary structure |
Spectroscopic and thermal techniques |
| Molecular Size |
Aggregates, fragments, molecular-size variants |
SEC-HPLC, CE-SDS |
| Charge |
Charge variants, isoelectric properties |
CEX-HPLC, iCIEF |
| Conjugation |
DAR, drug distribution, conjugation profile |
HIC-HPLC, LC-MS |
| Conjugation Sites |
Linker-payload attachment sites |
LC-MS/MS, peptide mapping |
| PTMs |
Glycosylation, oxidation, deamidation, etc. |
LC-MS/MS and complementary methods |
| Free Payload |
Unconjugated drug / payload-related species |
HPLC/UPLC, LC-MS |
| Biological Function |
Binding, potency, cellular activity |
Binding assays, cell-based assays |
The final analytical package is tailored to the ADC molecule, conjugation strategy, development stage, and intended use rather than applying a fixed testing panel to every program.
Orthogonal Characterization Strategy
ADC molecules contain multiple structural components and may exhibit heterogeneous drug loading, making orthogonal characterization particularly important.
Chromatographic Characterization
Chromatographic methods can provide information on molecular size, purity, charge heterogeneity, drug distribution, and payload-related impurities.
Representative techniques include:
- SEC-HPLC / UPLC
- HIC-HPLC
- Ion-exchange chromatography
- Reversed-phase HPLC / UPLC
- Other application-specific chromatographic approaches
Electrophoretic Characterization
Electrophoretic approaches can complement chromatographic analysis by evaluating molecular-size and charge-related characteristics.
Representative techniques include:
- CE-SDS
- iCIEF
- Other capillary electrophoresis-based methods
Mass Spectrometric Characterization
Mass spectrometry provides molecular-level information that can complement conventional chromatographic and electrophoretic methods.
Applications include:
- Intact mass analysis
- Reduced or subunit mass analysis
- Peptide mapping
- PTM characterization
- DAR assessment
- Conjugation site identification
- Structural variant characterization
Biophysical & Thermal Characterization
Biophysical approaches can be used to investigate structural integrity, conformational characteristics, thermal behavior, and aggregation propensity.
Depending on the ADC and study objectives, characterization can include:
- Spectroscopic analysis
- Thermal stability analysis
- Particle or aggregation assessment
- Other biophysical measurements
Comparability-Oriented Characterization
Although detailed comparability studies are addressed as part of the Stability & Comparability Studies service, structure and quality characterization provides the analytical foundation for such assessments.
Comparative characterization may examine:
- Molecular identity and mass
- Purity and molecular-size distribution
- Charge heterogeneity
- DAR and drug distribution
- Conjugation sites
- PTMs
- Higher-order structure
- Free payload
- Biological activity
Orthogonal characterization methods can be used to determine whether observed differences are analytical variation or meaningful changes in product quality.
Why Choose Protheragen
- Comprehensive ADC Characterization
Multiple analytical approaches can be combined to evaluate ADC identity, purity, molecular structure, conjugation characteristics, heterogeneity, and functional properties.
- Orthogonal Analytical Strategy
Complementary chromatographic, electrophoretic, mass spectrometric, biophysical, and functional approaches can be integrated to provide a more complete assessment of complex ADC molecules.
- Molecule-Specific Characterization
The analytical characterization package can be adapted to the ADC format, antibody, linker, payload, conjugation chemistry, and development objectives.
- Development-Stage Flexibility
Characterization strategies can evolve from early candidate assessment and process development to stability, comparability, and later-stage CMC activities.
Characterization data can be coordinated with analytical method development, process development, formulation development, stability studies, and manufacturing activities to maintain analytical continuity throughout the development lifecycle.
Comprehensive structure and quality characterization is essential for developing a detailed understanding of ADC molecular attributes and product heterogeneity. By combining orthogonal analytical approaches, Protheragen supports the characterization of molecular identity, structural integrity, DAR, conjugation sites, PTMs, molecular-size variants, charge heterogeneity, free payload, and functional properties. These characterization activities can support ADC process development, formulation optimization, stability investigations, comparability assessments, and broader CMC development, helping establish a scientifically supported understanding of product quality throughout the development lifecycle. Contact us to discuss your ADC structure and quality characterization requirements and develop a comprehensive analytical strategy tailored to your molecule and development stage.
Reference
- Dixit T, et al. "Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates." Discov Nano. 2025; 20(1):139
